CL2022002606A1 - Implante ocular que contiene un inhibidor de la tirosina cinasa - Google Patents
Implante ocular que contiene un inhibidor de la tirosina cinasaInfo
- Publication number
- CL2022002606A1 CL2022002606A1 CL2022002606A CL2022002606A CL2022002606A1 CL 2022002606 A1 CL2022002606 A1 CL 2022002606A1 CL 2022002606 A CL2022002606 A CL 2022002606A CL 2022002606 A CL2022002606 A CL 2022002606A CL 2022002606 A1 CL2022002606 A1 CL 2022002606A1
- Authority
- CL
- Chile
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- ocular implant
- implant containing
- hydrogel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere a un implante ocular biodegradable de liberación sostenida que contiene un inhibidor de la tirosina cinasa disperso en un hidrogel para el tratamiento de una enfermedad de la retina durante un período de tiempo prolongado.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062994391P | 2020-03-25 | 2020-03-25 | |
PCT/US2020/029827 WO2020219890A1 (en) | 2019-04-25 | 2020-04-24 | Ocular hydrogel tyrosine kinase inhibitor implants |
US202063106276P | 2020-10-27 | 2020-10-27 | |
US202163148463P | 2021-02-11 | 2021-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002606A1 true CL2022002606A1 (es) | 2023-03-24 |
Family
ID=77411313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002606A CL2022002606A1 (es) | 2020-03-25 | 2022-09-23 | Implante ocular que contiene un inhibidor de la tirosina cinasa |
Country Status (20)
Country | Link |
---|---|
US (4) | US20220079876A1 (es) |
EP (2) | EP4252725A3 (es) |
JP (2) | JP7378638B2 (es) |
KR (1) | KR20220157462A (es) |
CN (1) | CN115461040A (es) |
AU (2) | AU2021244485B2 (es) |
BR (1) | BR112022018815A2 (es) |
CA (2) | CA3171563A1 (es) |
CL (1) | CL2022002606A1 (es) |
DK (1) | DK3884929T3 (es) |
ES (1) | ES2952677T3 (es) |
FI (1) | FI3884929T3 (es) |
HR (1) | HRP20230800T1 (es) |
HU (1) | HUE062928T2 (es) |
IL (1) | IL296687A (es) |
MX (1) | MX2022010333A (es) |
PL (1) | PL3884929T3 (es) |
PT (1) | PT3884929T (es) |
TW (1) | TW202202138A (es) |
WO (1) | WO2021195163A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200337989A1 (en) * | 2019-04-25 | 2020-10-29 | Ocular Therapeutix, Inc. | Ocular hydrogel tyrosine kinase inhibitor implants |
BR112022018815A2 (pt) | 2020-03-25 | 2022-11-29 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor de tirosina cinase |
EP4236943A4 (en) * | 2020-10-27 | 2024-04-24 | Ocular Therapeutix Inc | EYE IMPLANT WITH AN ACTIVE INGREDIENT |
WO2022204374A1 (en) * | 2021-03-24 | 2022-09-29 | Ocular Therapeutix, Inc. | Implant injector device |
WO2023133276A1 (en) * | 2022-01-09 | 2023-07-13 | Ocular Therapeutix, Inc. | Intracanalicular insert comprising a non-steroidal anti-inflammatory agent |
WO2023133278A1 (en) * | 2022-01-09 | 2023-07-13 | Ocular Therapeutix, Inc. | Intracanalicular insert comprising an antimicrobial agent |
WO2023141249A1 (en) * | 2022-01-24 | 2023-07-27 | Celanese Eva Performance Polymers Llc | Implantable device for delivery of a tyrosine kinase inhibitor |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993071A (en) | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
US3949750A (en) | 1974-10-07 | 1976-04-13 | Freeman Jerre M | Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same |
US4915684A (en) | 1988-06-21 | 1990-04-10 | Mackeen Donald L | Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus |
US5469867A (en) | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
US6027470A (en) | 1998-06-10 | 2000-02-22 | Eagle Vision, Inc. | Punctum plug and method for inserting the same into the punctual opening |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
US6196993B1 (en) | 1998-04-20 | 2001-03-06 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
US6703047B2 (en) | 2001-02-02 | 2004-03-09 | Incept Llc | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US7347850B2 (en) | 1998-08-14 | 2008-03-25 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
US6509327B1 (en) | 1998-09-30 | 2003-01-21 | Alcon Manufacturing, Ltd. | Compositions and methods for treating otic, ophthalmic and nasal infections |
AU2707500A (en) | 1998-12-04 | 2000-06-26 | Incept Llc | Biocompatible crosslinked polymers |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
WO2001044401A1 (en) | 1999-12-17 | 2001-06-21 | Magnus Qvist | New use of a bioadhesive composition comprising a polyphenolic protein |
US20040175410A1 (en) | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
US6982090B2 (en) | 2001-05-10 | 2006-01-03 | Gillespie Donald E | More easily visualized punctum plug configurations |
US7090681B2 (en) | 2002-09-18 | 2006-08-15 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
US20050283109A1 (en) | 2003-03-07 | 2005-12-22 | Peyman Gholam A | Method and apparatus for lacrimal canal obstruction |
US20050197614A1 (en) | 2004-03-04 | 2005-09-08 | Wilson Pritchard | Occlusive biomedical devices, punctum plugs, and methods of use thereof |
US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US20080124400A1 (en) | 2004-06-24 | 2008-05-29 | Angiotech International Ag | Microparticles With High Loadings Of A Bioactive Agent |
EP1652552B1 (en) | 2004-11-02 | 2008-09-17 | Sydney Biotech Pty. Ltd. | Extraocular device |
AU2005300317A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole |
US8939910B2 (en) | 2006-03-28 | 2015-01-27 | Devicor Medical Products, Inc. | Method for enhancing ultrasound visibility of hyperechoic materials |
US11129690B2 (en) | 2006-03-28 | 2021-09-28 | Devicor Medical Products, Inc. | Method for making hydrogel markers |
SG170816A1 (en) | 2006-03-31 | 2011-05-30 | Qlt Plug Delivery Inc | Drug delivery methods, structures, and compositions for nasolacrimal system |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US9173773B2 (en) | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
CA2662902C (en) | 2006-09-15 | 2015-11-24 | Xcovery, Inc. | Kinase inhibitor compounds |
US20080114076A1 (en) | 2006-11-09 | 2008-05-15 | Alcon Manufacturing Ltd. | Punctal plug comprising a water-insoluble polymeric matrix |
US8080593B2 (en) | 2006-11-29 | 2011-12-20 | University Of Southern California | Reversible thermoresponsive adhesives for implants |
US8673286B2 (en) | 2007-04-09 | 2014-03-18 | Northwestern University | DOPA-functionalized, branched, poly(aklylene oxide) adhesives |
US20090227981A1 (en) | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
MX2009010761A (es) | 2007-04-05 | 2009-10-28 | Pfizer Prod Inc | Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos. |
US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
AU2010213612B2 (en) | 2009-02-12 | 2015-04-30 | Incept, Llc | Drug delivery through hydrogel plugs |
US20100247606A1 (en) | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
RU2554854C9 (ru) | 2009-07-31 | 2017-02-03 | Асцендис Фарма Ас | Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля |
KR101756493B1 (ko) | 2009-10-29 | 2017-07-10 | 아센디스 파마 에이에스 | 생분해성 하이드로겔의 살균 |
US9320647B2 (en) | 2010-03-31 | 2016-04-26 | Ocuject, Llc | Device and method for intraocular drug delivery |
US8821457B2 (en) | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
US20130202587A1 (en) | 2011-08-25 | 2013-08-08 | Randox Laboratories Ltd. | Identification of genetic variants |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
EP3613413A1 (en) | 2011-12-05 | 2020-02-26 | Incept, LLC | Medical organogel processes and compositions |
US11779682B2 (en) | 2012-04-30 | 2023-10-10 | The Johns Hopkins University | Electro-mechanically stretched micro fibers and methods of use thereof |
WO2013165975A1 (en) | 2012-04-30 | 2013-11-07 | The Johns Hopkins University | Electro-mechanically stretched micro fibers and methods of use thereof |
WO2013177367A2 (en) | 2012-05-23 | 2013-11-28 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
EP2916827B1 (en) | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
KR102210895B1 (ko) | 2013-03-08 | 2021-02-02 | 폴리액티바 피티와이 리미티드 | 생리활성 물질의 전달을 위한 폴리머 결합체 |
US10113033B2 (en) | 2013-03-08 | 2018-10-30 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
RU2015146211A (ru) | 2013-04-01 | 2017-05-19 | Аллерган, Инк. | Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения |
US20160296627A1 (en) | 2013-12-06 | 2016-10-13 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
WO2015108787A2 (en) | 2014-01-16 | 2015-07-23 | Retinal Therapies LLC | Compositions and methods for the treatment of intraocular neovascularization and/or leakage |
MX2016010082A (es) | 2014-02-04 | 2016-10-07 | Pfizer | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer. |
KR20150115533A (ko) * | 2014-04-04 | 2015-10-14 | 씨제이제일제당 (주) | 1,5-디아미노펜탄의 정제방법 |
JP7092502B2 (ja) | 2014-12-10 | 2022-06-28 | インセプト・リミテッド・ライアビリティ・カンパニー | ハイドロゲル薬物送達インプラント |
WO2016178150A1 (en) | 2015-05-05 | 2016-11-10 | Shilpa Medicare Limited | Novel polymorphs of axitinib |
EP4279064A3 (en) * | 2015-05-12 | 2024-02-28 | Incept, LLC | Drug delivery from hydrogels |
KR20240043821A (ko) | 2015-06-06 | 2024-04-03 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
IL256245B (en) | 2015-06-16 | 2022-09-01 | Merck Patent Gmbh | Treatments that combine a pd-l1 antagonist |
CN107949354B (zh) | 2015-07-22 | 2022-02-18 | 因赛普特有限责任公司 | 涂覆的泪点塞 |
WO2017015616A1 (en) | 2015-07-22 | 2017-01-26 | Envisia Therapeutics, Inc. | Ocular protein delivery |
KR20180086468A (ko) | 2015-11-25 | 2018-07-31 | 인셉트, 엘엘씨 | 형상 변형 약물 전달 장치 및 방법 |
KR102408596B1 (ko) | 2016-06-02 | 2022-06-13 | 에이디에스 테라퓨틱스 엘엘씨 | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 |
AU2017331444B2 (en) * | 2016-09-23 | 2023-08-17 | Incept, Llc | Intracameral drug delivery depots |
PL3502105T3 (pl) | 2016-09-29 | 2022-07-11 | Equinox Sciences, Llc. | Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie |
CN110022794A (zh) | 2016-10-05 | 2019-07-16 | 泰坦医药品公司 | 具有减少的突释的用于药物递送的可植入装置 |
MX2019014942A (es) | 2017-06-13 | 2020-02-19 | Eyepoint Pharmaceuticals Inc | Dispositivos de administracion de farmacos bioerosionables. |
EP3765083A1 (en) | 2018-03-16 | 2021-01-20 | Novartis Ag | Methods for treating ocular diseases |
US20200306182A1 (en) | 2019-03-05 | 2020-10-01 | Aerie Pharmaceuticals, Inc. | Pharmaceutical compositions for treating ocular diseases or disorders |
US20200337989A1 (en) | 2019-04-25 | 2020-10-29 | Ocular Therapeutix, Inc. | Ocular hydrogel tyrosine kinase inhibitor implants |
WO2020243608A1 (en) | 2019-05-31 | 2020-12-03 | Dose Medical Corporation | Bioerodible polyester polymer implants and related methods of use |
BR112022018815A2 (pt) | 2020-03-25 | 2022-11-29 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor de tirosina cinase |
US20220080044A1 (en) | 2020-09-14 | 2022-03-17 | National Yang-Ming University | Method for preventing or treating peripheral arterial occlusive disease |
-
2021
- 2021-03-24 BR BR112022018815A patent/BR112022018815A2/pt unknown
- 2021-03-24 PT PT211647375T patent/PT3884929T/pt unknown
- 2021-03-24 KR KR1020227036590A patent/KR20220157462A/ko not_active Application Discontinuation
- 2021-03-24 CN CN202180030126.1A patent/CN115461040A/zh active Pending
- 2021-03-24 JP JP2022557121A patent/JP7378638B2/ja active Active
- 2021-03-24 US US17/210,719 patent/US20220079876A1/en not_active Abandoned
- 2021-03-24 PL PL21164737.5T patent/PL3884929T3/pl unknown
- 2021-03-24 CA CA3171563A patent/CA3171563A1/en active Pending
- 2021-03-24 WO PCT/US2021/023806 patent/WO2021195163A1/en active Application Filing
- 2021-03-24 ES ES21164737T patent/ES2952677T3/es active Active
- 2021-03-24 EP EP23172378.4A patent/EP4252725A3/en active Pending
- 2021-03-24 DK DK21164737.5T patent/DK3884929T3/da active
- 2021-03-24 HU HUE21164737A patent/HUE062928T2/hu unknown
- 2021-03-24 CA CA3234679A patent/CA3234679A1/en active Pending
- 2021-03-24 HR HRP20230800TT patent/HRP20230800T1/hr unknown
- 2021-03-24 US US17/210,696 patent/US11439592B2/en active Active
- 2021-03-24 TW TW110110719A patent/TW202202138A/zh unknown
- 2021-03-24 FI FIEP21164737.5T patent/FI3884929T3/fi active
- 2021-03-24 IL IL296687A patent/IL296687A/en unknown
- 2021-03-24 EP EP21164737.5A patent/EP3884929B1/en active Active
- 2021-03-24 MX MX2022010333A patent/MX2022010333A/es unknown
- 2021-03-24 AU AU2021244485A patent/AU2021244485B2/en active Active
-
2022
- 2022-05-13 US US17/744,189 patent/US11534396B2/en active Active
- 2022-09-23 CL CL2022002606A patent/CL2022002606A1/es unknown
- 2022-11-21 US US17/991,762 patent/US20230118774A1/en active Pending
-
2023
- 2023-10-31 JP JP2023186255A patent/JP2024012435A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203448A patent/AU2024203448A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210308043A1 (en) | 2021-10-07 |
US20230118774A1 (en) | 2023-04-20 |
ES2952677T3 (es) | 2023-11-03 |
MX2022010333A (es) | 2022-12-08 |
JP7378638B2 (ja) | 2023-11-13 |
EP3884929A1 (en) | 2021-09-29 |
KR20220157462A (ko) | 2022-11-29 |
HUE062928T2 (hu) | 2023-12-28 |
BR112022018815A2 (pt) | 2022-11-29 |
EP4252725A2 (en) | 2023-10-04 |
AU2021244485A1 (en) | 2022-09-15 |
IL296687A (en) | 2022-11-01 |
CN115461040A (zh) | 2022-12-09 |
US11534396B2 (en) | 2022-12-27 |
PT3884929T (pt) | 2023-08-09 |
US20220079876A1 (en) | 2022-03-17 |
AU2021244485B2 (en) | 2024-05-16 |
US11439592B2 (en) | 2022-09-13 |
WO2021195163A1 (en) | 2021-09-30 |
EP4252725A3 (en) | 2023-11-22 |
JP2024012435A (ja) | 2024-01-30 |
CA3171563A1 (en) | 2021-09-30 |
DK3884929T3 (da) | 2023-09-25 |
US20220347094A1 (en) | 2022-11-03 |
PL3884929T3 (pl) | 2023-10-09 |
TW202202138A (zh) | 2022-01-16 |
JP2023518820A (ja) | 2023-05-08 |
CA3234679A1 (en) | 2021-09-30 |
HRP20230800T1 (hr) | 2023-10-27 |
EP3884929B1 (en) | 2023-06-14 |
FI3884929T3 (fi) | 2023-08-07 |
AU2024203448A1 (en) | 2024-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022002606A1 (es) | Implante ocular que contiene un inhibidor de la tirosina cinasa | |
CO6351718A2 (es) | Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular | |
CY1120299T1 (el) | Μειωση ενδοφθαλμιας πιεσης με ενδοθαλαμικα εμφυτευματα βιματοπροστης | |
CY1121865T1 (el) | Οφθαλμολογικες συνθεσεις και η χρηση τους | |
CR10041A (es) | Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares | |
PH12019500423A1 (en) | Pharmaceutical composition | |
UY30058A1 (es) | (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa | |
BR112015022161A2 (pt) | implante intraocular contendo prostamida | |
MX2020005240A (es) | Sistemas y metodos para cirugia laser ocular y tratamientos terapeuticos. | |
CY1115565T1 (el) | Μεθοδος και συνθεση για την αγωγη της οφθαλμικης υπερτασεως και του γλαυκωματος | |
CO6420401A2 (es) | Método y aparato para limitar el crecimiento de la longitud del ojo | |
AR048645A1 (es) | Tratamientos para el implante ocular de efecto terapeutico prolongado | |
UY30060A1 (es) | Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos | |
ES2538551B1 (es) | Composición Oftálmica para la corrección de la presbicia | |
CL2007002386A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica. | |
MX2020004730A (es) | Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada. | |
EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
BRPI0708802B8 (pt) | implante intracorneal pré-formado para anormalidades ou distrofias corneais | |
MX2023004614A (es) | Implante ocular que contiene un agente activo. | |
EA201290958A1 (ru) | Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств | |
MX2022009435A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares. | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
JP1747385S (ja) | 流体交換具 | |
Bansal et al. | Comparison of the effect of topical bromfenac with nepafenac in maintaining mydriasis during cataract surgery | |
DOP2021000098A (es) | Asesor de procedimiento corneal topográfico inteligente |